Procter & Gamble stock holds at $143 as restructuring costs weigh on fiscal 2027 outlook
Published on 08/31/2026 at 17:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Procter & Gamble Co. (ISIN US7427181091) stock is trading in the mid-$140 range as of late August 2026, with investors balancing resilient fiscal 2026 results against a sizable restructuring program that will reshape the consumer-products portfolio through fiscal 2027. As of August 30, 2026, detailed coverage cited a NYSE share price of $143.71 alongside a consensus target of $161.19, a gap of $17.48 that points to a discount of just over 12 percent versus analyst expectations per one recent overview recent valuation coverage.
While the share price remains supported by strong margins and an annual dividend of $4.35 per share, attention on August 31, 2026 is turning to how a planned restructuring, projected to cost between $1 billion and $1.6 billion before tax over roughly two years, will interact with the company’s guidance for fiscal 2027. That plan includes streamlining brands, formats, and marketing methods and could trim projected organic sales growth for the period by 0.3 to 0.5 percentage points according to recent reports coverage of the restructuring plan. For investors, the question is how much of this impact is already embedded in the stock’s valuation discount versus the consensus price target.
Fiscal 2026 revenue, profit, and cash flow
Procter & Gamble closed its fiscal year ended June 2026 with revenue of $87 billion, representing annual growth of 3 percent compared with the prior year according to recent fiscal-year commentary a fiscal 2026 overview. Net profit for the same period was reported at $16.1 billion, highlighting the company’s ability to convert a mid-single-digit top-line increase into substantial bottom-line earnings. The company also generated operating cash flow of $19.6 billion in fiscal 2026, underlining the cash-generative nature of its household and personal-care franchises.
These figures provide a useful comparison against the stock’s current price band. With a market price in the low-$140s and annual earnings above $16 billion, Procter & Gamble’s valuation is framed by both its cash flow strength and its dividend policy. The annualized dividend of $4.35 per share mentioned in late August coverage corresponds to a dividend yield in the vicinity of 3 percent at the referenced $143.71 price, a level that remains attractive when paired with the company’s defensive product mix late August dividend data. The ability to sustain this payout is anchored in the $19.6 billion operating cash flow reported for the fiscal year ended June 2026.
Restructuring impact and fiscal 2027 guidance
Beyond the historical fiscal 2026 results, investors are now concentrating on the impact of Procter & Gamble’s restructuring program, which is scheduled to be largely completed by the end of fiscal 2027. The company has indicated that the total pretax cost of this reorganization will fall between $1 billion and $1.6 billion over around two years, creating a modest drag on near-term profitability but aiming to improve efficiency and focus the brand portfolio for the longer term restructuring cost details.
Recent commentary suggests that removing selected brands, formats, and marketing approaches could reduce projected organic sales growth for the restructuring period by 0.3 to 0.5 percentage points. In practical terms, a hypothetical 4 percent organic growth trajectory could ease to a range between 3.5 percent and 3.7 percent once this drag is accounted for. For valuation, the key comparison lies between this slightly softer organic growth outlook and the current discount of more than 12 percent between the consensus price target of $161.19 and the late August trading level at $143.71 consensus target and discount data. The numbers suggest that the market is assigning a meaningful, though not extreme, risk premium to the transition period.
At the same time, the company has highlighted that most restructuring actions should be completed by the end of fiscal 2027, limiting the duration of the headwind. Once the program is finished, the intended benefits include a more streamlined product lineup and potentially improved margin resilience. The reported fiscal 2026 net profit of $16.1 billion and operating cash flow of $19.6 billion underscore that Procter & Gamble enters this phase from a position of financial strength, providing room to absorb the $1 billion to $1.6 billion restructuring cost while maintaining its shareholder-return policies profitability and cash flow context.
Valuation signals and discounted cash flow view
In parallel to the consensus price target of $161.19, some valuation work using discounted cash flow modeling has produced a lower intrinsic value estimate for Procter & Gamble’s shares. One such analysis places the earnings-based intrinsic value at $89.98 and the free-cash-flow-based intrinsic value at $73.57, and compares these numbers to a prevailing market price of $143.78. This comparison yields a margin of safety figure of negative 59.8 percent, suggesting the stock is trading well above that model’s estimate of fair value a discounted cash flow valuation overview.
For investors, this juxtaposition of a consensus target at $161.19 with a DCF-derived intrinsic value near $90 highlights divergent views on how sustainable Procter & Gamble’s current profitability and cash flow levels are over the long term. On the one hand, the fiscal 2026 revenue of $87 billion, net profit of $16.1 billion, and operating cash flow of $19.6 billion set a solid baseline for future dividends and buybacks. On the other hand, the negative margin of safety implied by the intrinsic value estimate signals that, under conservative growth and margin assumptions, the current share price in the mid-$140s could be considered rich relative to long-term cash flow projections comparison of price and DCF value.
Reconciling these perspectives involves looking at the near-term restructuring costs and the expected organic growth moderation. If the projected 0.3 to 0.5 percentage point reduction in organic sales growth during the restructuring period is temporary and the streamlined portfolio leads to improved margin performance beyond fiscal 2027, then the consensus view reflected in the $161.19 target may lean on a belief in post-restructuring earnings power. Conversely, if growth and margins settle structurally below historical levels, a lower intrinsic value closer to the DCF estimate of $89.98 could gain more traction among cautious investors organic growth impact data.
Core brands: Pampers as a representative product
One central pillar of Procter & Gamble’s business model is its portfolio of everyday consumer brands, with Pampers standing out as a representative product in the baby-care segment. Pampers diapers and related hygiene products are distributed globally and target parents seeking reliability and comfort in baby-care routines. This category directly contributes to the company’s large sales base, which reached $87 billion in fiscal 2026, and benefits from recurring purchase behavior that helps stabilize revenue across economic cycles portfolio context for Pampers.
Within the restructuring program, commentary has clarified that while selected brands and formats may be eliminated or repositioned, there has been no announcement regarding the worldwide closure of major lines such as Oral-B or Pampers. This indicates that Pampers remains a foundational brand for Procter & Gamble’s long-term strategy. The combination of strong brand recognition and the essential nature of baby-care products positions Pampers to continue supporting the company’s revenue and profit base even as the broader portfolio is optimized. For investors, this underscores that the restructuring is aimed more at trimming and focusing the assortment rather than exiting key franchises that underpin the $87 billion fiscal 2026 sales volume.
Procter & Gamble stock price context and investor view
From a market perspective, recent snapshots show Procter & Gamble stock trading around $143.71 to $143.96 as of late August 2026, based on coverage that references NYSE-listed shares and current data from investment portals a late August price snapshot a comparative price overview. One overview notes the stock at $143.76, up 0.43 percent on the day in its cited session, while another lists a current price of $143.96 with a modest intraday change. These readings align with the $143.71 level used in the valuation commentary and support a picture of the shares holding in a relatively tight trading range just below the consensus target.
As of August 30, 2026, 4:00 p.m. ET, Procter & Gamble stock closed at $143.71 on the NYSE late August closing price data. At that level, the discount to the $161.19 consensus price target stands at $17.48, which is more than 12 percent of the target value. For investors, the current situation can be summarized as follows: fiscal 2026 delivered $87 billion in revenue, $16.1 billion in net profit, and $19.6 billion in operating cash flow; a restructuring costing between $1 billion and $1.6 billion over around two years is expected to modestly reduce organic growth by 0.3 to 0.5 percentage points during the transition; and the stock trades in the mid-$140s with a dividend of $4.35 per share, leaving a yield in the region of 3 percent and a noticeable, though not decisive, discount to consensus valuation benchmarks.
Go deeper
Investors can explore more detailed discussions of Procter & Gamble stock valuation, dividend policy, and restructuring impact through specialized market-data and company-analysis platforms, which provide extended metrics such as forward earnings estimates, payout ratios, and segment-level performance for categories like baby-care, fabric-care, and grooming.
Investor Relations
More on Procter & Gamble stock can be found via the company’s investor relations page, including official presentations, filings, and updates on fiscal 2026 results and the ongoing restructuring program.
Fact box
Company: Procter & Gamble Co.
ISIN: US7427181091
Ticker: PG
Exchange: NYSE
Price (as of August 30, 2026, 4:00 p.m. ET): $143.71 USD
Sector / Industry: Consumer staples / Household and personal products
Index membership: S&P 500
